SABCS 2022 | The comprehensive genomic characterization of HER2-low breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, provides an overview of a comprehensive genomic characterization of HER2-low breast cancer. Patients who had undergone next generation sequencing (NGS) testing with a targeted, tumor-only platform (OncoPanel) were included in the investigated and were divided into HER2-low versus HER2-0 and depending on hormone receptor status. The genomic profiles of patients with HER2-low and HER2-0 were compared. Among all mutational events, any mutation in MPL, CYLD, and MAP3K and oncogenic mutations in TP53 and NF1 were more common in HER2-0, while any mutation in MTOR, RAD21, DNMT3A, and PDGFRA were enriched in HER2-low patients, when controlling for ER status. However, no mutation reached significance after accounting for multiple hypothesis testing. These findings suggest HER2-low and HER2-0 are not distinct molecular entities, despite that HER2-low can be targeted with HER2-directed antibody-drug conjugates (ADCs). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.